Meningococcal vaccine groups A and C conjugate - Baxter International
Latest Information Update: 12 Oct 2006
At a glance
- Originator Baxter International
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Meningococcal group A infections; Meningococcal group C infections
Most Recent Events
- 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International
- 04 Dec 1997 Phase-I clinical trials for Meningococcal group A infections in Canada (Unknown route)
- 04 Dec 1997 Phase-I clinical trials for Meningococcal group A infections in USA (Unknown route)